1.
Eur Ann Allergy Clin Immunol
; 43(2): 58-60, 2011 Mar.
Article
in English
| MEDLINE
| ID: mdl-21608374
ABSTRACT
A 3-year prospective post marketing survey on the safety of the recently developed ultrashort pre-seasonal subcutaneous immunotherapy (uSCIT-MPL4) with pollen allergoids adjuvanted with monophosphoryl lipid A was performed. A total of 510 patients received uSCIT-MPL4, 61% for grass, 35.7% for birch, 13.2% for parietaria and 3% for other pollens (ragweed, mugwort, and olive). A total of 3308 injections were given and the mean duration of uSCIT-MPL-4 was 2.3 years. Overall, only 7 slight systemic reactions (SR) were observed in 510 patients (1.37%) and 2.11/1000 injections suggesting that this treatment is even safer than traditional depot injection SIT.
Subject(s)
Adjuvants, Immunologic/administration & dosage , Desensitization, Immunologic/adverse effects , Lipid A/analogs & derivatives , Plant Extracts/adverse effects , Adult , Allergoids , Female , Humans , Italy , Lipid A/administration & dosage , Male , Middle Aged , Prospective Studies
2.
G Clin Med
; 64(7-8): 278-83, 1983.
Article
in Italian
| MEDLINE
| ID: mdl-6642111
Subject(s)
Anti-Bacterial Agents/therapeutic use , Bronchitis/drug therapy , Pneumonia/drug therapy , Ribostamycin/therapeutic use , Adult , Aged , Drug Evaluation , Female , Humans , Male , Middle Aged
3.
Lijec Vjesn
; 103(2-3): 87-91, 1981.
Article
in Croatian
| MEDLINE
| ID: mdl-7311707
Subject(s)
Bronchial Neoplasms/epidemiology , Lung Neoplasms/epidemiology , Adult , Aged , Female , Humans , Italy , Male , Middle Aged
4.
Med Lav
; 66(5): 453-5, 1975.
Article
in Italian
| MEDLINE
| ID: mdl-1221290
